Compare KE Holdings Inc (BEKE) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KE Holdings Inc vs Incyte Corporation — how do they compare? KE Holdings Inc trades at $17.28 (market cap $18.92B), while Incyte Corporation trades at $121.25 (market cap $24.54B). The key difference: Incyte Corporation is the larger of the two by market cap, and KE Holdings Inc pays a 1.63% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| BEKE | INCY | |
|---|---|---|
Market Cap | $18.92B | $24.54B |
Sector | Technology | Health |
52-Week High | $20.36 | $129.93 |
52-Week Low | $14.26 | $81.61 |
Enterprise Value | $14.66B | $20.04B |
Dividend Yield | 1.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BEKE trades at $17.23, down 2.38% today, with a bullish technical signal supported by moving averages. The company reported strong Q1 2026 results, beating EPS estimates with $0.20 vs. $0.14 expected, while revenue declined to $90.1B in 2026 from $94.6B in 2025. Analyst sentiment remains overwhelmingly positive with 91.67% buy ratings. Cash flow trends show improvement with operating cash flow turning positive in 2026 at $2.1B.
The outlook appears favorable with improving profitability and strong analyst support, though risks include revenue contraction and China's property market exposure. The stock's current valuation at P/E 38.53 appears elevated but is supported by earnings growth potential and market leadership position in Chinese housing services.
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About KE Holdings Inc
KE Holdings (Beike) is China’s leading platform for housing transactions and services. It operates the Lianjia brand and uses data-driven technology to facilitate home sales, rentals, and home renovation services.
Read more on BEKE →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
